ANTIBODY-MEDIATED REJECTION IN LIVER TRANSPLANTATION- AN UNRESOLVED PUZZLE

Antibody-mediated rejection (AMR) in liver transplantation is a frequently underestimated contributor to allograft injury. Despite advancements in defining acute and chronic AMR, challenges persist in timely identification and effective management. The complexities arise from the intricate nature of diagnosis, the absence of standardized treatment protocols, and uncertainties regarding long-term outcomes.